Please login to the form below

Not currently logged in
Email:
Password:

Bayer signs strategic CRO partnership with Covance

Deal covers R&D services in clinical drug development

Bayer has agreed a long-term contract research organisation (CRO) partnership deal that will see the pharma company outsource some of its clinical drug development work to Covance.

The agreement will see Covance provide R&D services related to the German pharma company's phase II-IV clinical trials as well as central laboratory services.

Bayer has worked with Covance for a number of years and said its goal now was to make better use of Covance's broad range of experience and services to give it best-in-class operational delivery, efficiency and quality.

As with many outsourcing deals the pharma company also has its eye on the bottom line and noted that its agreement with Covance would deliver “significant financial benefits to both organisations”.

Bayer's head of global development Kemal Malik said the agreement would give both partners an opportunity to develop a “broader-based partnership in the future to deliver mutual benefits”.

John Watson, president of strategic partnering and chief commercial officer at Covance, said his company had already “established an enduring relationship with Bayer”.

He added: “We look forward to working together with Bayer HealthCare to identify opportunities to leverage our broad portfolio to generate more efficiencies thereby reducing the overall time and cost of drug development.”

The tie-up follows a number of prominent pharma-CRO deals this year, including Amgen's biosimilar deal with PRA, a global agreement between Astellas and INC Research and Lilly's partnership with Chinese CRO Shangpharma.

31st May 2012

Share

Related Hub content

    Your search did not contain any words. Please try again.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Chandler Chicco Companies US

Chandler Chicco Companies (CCC) is a global health communications group that delivers unmatched perspective and creative know-how. Today, healthcare is...

Latest intelligence

Easier access to medicines in the UK?
Cutting through the NICE value-based assessment consultation to find out what’s at stake...
Exploring MINT: Part 3 - Nigeria
In the third of a series of posts focusing on each of the ‘MINT’ markets, I take an in-depth look at the opportunities and challenges for pharma in Nigeria....
BL_Where_Now_20140721_CoverImage.jpg
3 Steps to Navigating Multichannel in Healthcare
You know about multichannel, but... where now? Download the 3 Steps to Navigating Multichannel in Healthcare ebook to learn what you should do next when planning your multichannel campaign....